Preclinical ADME Tox Contract Research

Apredica is a preclinical Contract Research Organization (CRO) that provides services to optimize and evaluate ADME, Toxicity and Pharmacokinetic properties of drug candidates and lead compounds early in the drug discovery process. In August 2010 Apredica (Watertown, MA) was acquired by Cyprotex (Macclesfield, UK) and now functions as their United States base of operations. As a wholly-owned subsidiary of Cyprotex, Apredica has continued to develop and validate industry-leading technologies, and now offers a High Content Screening Prediction system - CellCiphr^®, that assists in evaluating potential toxic liabilities of compounds and genomic ADME (gADME™), a technology that combines genomic information about drug metabolizing enzymes and their alleles with ADME. As we expand the service offering for our clients, we remain dedicated to providing top-quality Caco-2 permeability and bioanalytical assays as part of a wide array of preclinical testing services.

Contact us to learn more about how Apredica can assist with your company's preclinical ADME, Toxicology, and PK studies.

Why Apredica for Preclinical ADME Tox?

• Trusted for Quality
  Apredica has grown every year since it was founded in 2005. We performed 485 studies in 2012, and our business has consistently increased year-to-year, anywhere from 10% - 42% in the past three years. We earn our reputation for reliability and quality data through our returning customers who have consistently accounted for over 80% of our business.


• Scientist-to-Scientist Communications
  All accounts are served by Scientist Study Managers, who are assigned to work on specific client-focued projects.


• Fast Turnaround
  ADME Tox results in just days. Courier pickup in Cambridge, Watertown and greater Boston.


• Service-Focused CRO - No Internal Drug-Discovery Program
  The only drug-discovery programs Apredica advances are those of our clients.


• Drug-Discovery Expertise - High Ph.D. Ratio
  Apredica's scientists each have more than 10 years of drug-discovery experience. 80% have Ph.D.s. This allows us to customize work to fit clients' needs.

Contact us to discuss how Apredica's ADME Tox testing services can help your organization increase the speed of drug discovery while reducing costs.